NBIX News and Press, Neurocrine Biosciences Inc. From 03/03/23

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting PR Newswire SAN DIEGO , March 3, 2023 ...

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide ther...

Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference PR Newswire SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 ...

The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Neurocrine Biosciences, Inc. 2022 Q4 - Results - Earnings Call Presentation

Start Time: 08:00 End Time: 09:02 Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief ...

Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q4 Non-GAAP EPS of $1.24 misses by $0.20 . Revenue of $412M (+32.1% Y/Y) beats by $3.04M . INGREZZA fourth quarter and fiscal 2022 net product sales were $399 million and $1.43 billion, respectively INGREZZA ...

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 PR Newswire INGREZZA ® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA ® (valbenazine) 2023 ...

Summary Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use of Ingrezza as a treatment for Huntington's chorea. Ingrezza, with its clin...

Neurocrine Biosciences ( NASDAQ: NBIX ) added ~4% pre-market Friday after Morgan Stanley upgraded the commercial-stage drug developer to Overweight from Equal Weight, citing FDA approval for its lead asset Ingrezza for Huntington's disease chorea. Ingrezza is already approved in t...

Summary Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February. The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatm...